Daily Briefing | 16 November 2026: The Kremlin announces that the leaders of China, the US and Russia will meet in Shenzhen on 19 November; the FT reports that Jensen Huang is considering a return to Nvidia; 107 new medicines added to the 2026 National Reimbursement Drug List; Starship successfully catches upper stage with tower arm for the first time; first launch of the Vulcan rocket fails; Bitcoin falls to a three-month low

Daily Briefing | 16 November 2026: The Kremlin announces that the leaders of China, the US and Russia will meet in Shenzhen on 19 November; the FT reports that Jensen Huang is considering a return to Nvidia; 107 new medicines added to the 2026 National Reimbursement Drug List; Starship successfully catches upper stage with tower arm for the first time; first launch of the Vulcan rocket fails; Bitcoin falls to a three-month low

AdenXie

Automatically translated. Read the Chinese original.

Today's main theme

This edition covers the period from 14 November (Saturday) to 15 November (Sunday), with the ‘Space News’ section looking back at the launch on the evening of 13 November. There is no stock market trading at the weekend, but this week’s schedule is already packed with important events. On the diplomatic front, the Kremlin has stated that Putin, Xi Jinping and Trump will hold their first trilateral meeting on 19 November during the APEC summit in Shenzhen. The US has indicated that the agenda will cover nuclear arms control and the war in Iran, whilst Russia has stated that the talks will focus on Ukraine; none of the parties expect an agreement to be reached. On the AI front, according to the *Financial Times*, Jensen Huang—who resigned just three days ago—is discussing a return to NVIDIA with those close to him, whilst Silicon Valley supporters are lobbying the board and the White House. NVIDIA is due to release its financial results on 17 November, with interim CEO Kress set to chair his first earnings call. On the domestic front, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security have published the 2026 edition of the National Medical Insurance Drug Catalogue, adding 107 new medicines, including 51 Category 1 innovative drugs – a record high. In the technology sector, SpaceX’s Starship upper stage was successfully caught by a launch tower robotic arm for the first time after orbiting the Earth for approximately 22.5 hours; one day later, a ULA Vulcan rocket carrying 40 Amazon Leo satellites failed to launch, marking the first complete failure since ULA’s inception. In the markets, Bitcoin fell to around US$63,000 over the weekend, its lowest level since August, with expectations of interest rate rises and outflows from ETFs continuing to weigh on risk assets.

Key News

1. The Kremlin stated that the leaders of China, the US and Russia held their first trilateral meeting in Shenzhen on 19 November, with each side presenting its own version of the agenda

According to Turkey’s Anadolu Agency, Kremlin spokesman Peskov told TASS on Saturday 14 November that the parties had agreed to hold a trilateral meeting on 19 November, to be held in Shenzhen during the APEC Leaders’ Meeting on 18–19 November. According to reports compiled by HNGN, the White House has also confirmed this meeting, which will mark the first trilateral meeting between the leaders of the United States, China and Russia. As of the afternoon of 15 November, the Chinese Ministry of Foreign Affairs had not yet publicly confirmed the specific date, having previously stated only that it was “maintaining communication with the relevant parties”.

There are differing accounts of the agenda from various quarters. According to HNGN, senior US officials have stated that nuclear weapons and the war in Iran will be on the agenda, whilst the Ukraine issue will not; Trump had previously called for a ‘new, improved and modernised’ arms control treaty that would include China. Kremlin aide Ushakov, however, stated that Putin and Trump would continue to discuss “the full range of issues” concerning Ukraine in Shenzhen. According to a report republished by Yahoo News, *The New York Post* claimed that the meeting would discuss preparations for a nuclear arms control agreement. China has historically taken a negative stance on joining arms control negotiations; in 2025, a Foreign Ministry spokesperson stated that demanding China’s participation was “neither reasonable nor realistic”. Ukrainian Foreign Minister Serbiha said that such a meeting would only be counterproductive. Officials from all sides expect that no agreement will be reached, nor will any separate bilateral talks between Putin and Trump be arranged.

The mere fact that the leaders of the three nations are appearing together is symbolic in itself: as the host, China can demonstrate its role as a mediator; the US wishes to draw China into the arms control framework; whilst Russia hopes to bypass Europe on the issue of Ukraine. For the markets, this meeting may influence geopolitical risk premiums, including oil prices, European gas prices and expectations regarding US-China trade. On the agenda, Trump will first travel to Manila on 16 November to attend the ASEAN Summit, with the APEC meeting opening on 18 November, followed by the G20 Summit in Miami on 14–15 December. Key points to watch going forward include whether China formally confirms the meeting, whether a joint statement is issued afterwards, and developments in the situations regarding Iran and the Russia–Ukraine conflict before and after the meeting.

Source:Anadolu Agency、HNGN、Yahoo News

2. The Financial Times reports that Huang Renxun is considering returning as CEO of Nvidia, adding further uncertainty on the eve of the earnings report

According to a Reuters report citing a Financial Times article dated 15 November (Sunday), Jensen Huang is considering returning as CEO of Nvidia and has discussed this possibility with close associates; Bloomberg also cited this report. He resigned as CEO and from the board on 12 November, just a few days ago. According to Startup Fortune, the FT quoted an ally as saying that supporters are setting up a “war room” comprising Silicon Valley executives to lobby the board and seek White House backing; Elon Musk and Epic Games CEO Sweeney are reportedly backing this move; Huang’s spokesperson declined to comment. Gester of Altimeter and Baker of Atreides wrote to the board on Friday, suggesting that all options – including Huang’s return – should be kept open.

The board’s stance is far more cautious. According to the same report, Nvidia’s board stated that it is in the process of selecting an executive search firm, has not yet formally approached any candidates, and that it is too early to discuss specific individuals; Board Chairman Jones expressed his full confidence in interim CEO Kress, whilst the independent investigation is still ongoing. Treasurer Bessent believes NVIDIA should seek a CEO from outside the company, whilst Ives of Wedbush believes there is no possibility of Jensen Huang returning. The prediction market Polymarket puts the odds of his return at approximately 3 per cent.

The financial results themselves are also crucial. According to The Motley Fool, Nvidia has provided revenue guidance for this quarter of approximately US$108 billion (plus or minus 2 per cent), with a gross margin of around 74 per cent—down from 75 per cent in the previous quarter—due to rising memory costs; the company has also indicated that the gross margin for the fourth quarter may fall to between 71 per cent and 72 per cent; The market generally expects revenue of around US$109 billion and adjusted earnings per share of US$2.47. NVIDIA’s share price has already fallen by more than 30 per cent from its October high. Key points to watch: data centre revenue figures and fourth-quarter guidance on 17 November; how Cress will organise Huang Renxun’s former responsibilities; and whether the board will address rumours of his return.

Source:Investing.com (Reuters)、Bloomberg、Startup Fortune、The Motley Fool

3. The 2026 edition of the National Medical Insurance Drug List has been published: 107 new medicines have been added, including 51 Category 1 innovative medicines; it will come into effect on 1 January 2027.

On 14 November, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the 2026 edition of the National Catalogue of Medicines for Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance, as well as the Catalogue of Innovative Medicines for Commercial Health Insurance. According to an announcement by the National Medical Insurance Bureau, the new catalogue includes 107 new medicines, of which 51 are Category 1 innovative medicines, whilst 34 have been removed. Following these adjustments, the catalogue now comprises a total of 3,331 medicines, including 1,935 Western medicines, 1,396 proprietary Chinese medicines and 885 Chinese herbal decoction pieces. The new catalogue will come into effect on 1 January 2027.

According to Xinhua News Agency (reprinted by Guangming Online), the newly added medicines include 31 anti-cancer drugs, 24 medicines for chronic diseases, 18 medicines for rare diseases, 11 traditional Chinese patent medicines, 7 anti-infective medicines and 5 medicines for mental disorders. Huang Xinyu, Director-General of the Department of Medical Services Management at the National Medical Insurance Bureau, stated that this adjustment prioritises the inclusion of innovative medicines with clear clinical benefits that can fill treatment gaps. Twelve new innovative medicines have been added to the commercial health insurance catalogue, bringing the total to 28. According to The Paper, these include the world’s first CAR-T therapy for solid tumours and China’s first gene therapy for haemophilia. Xinhua also noted that in the first ten months of 2026, medical insurance fund expenditure on negotiated medicines within the agreement period exceeded 120 billion yuan.

For the pharmaceutical industry, inclusion in the national medical insurance scheme means trading price for volume; the selection of 51 Class 1 new drugs indicates that domestically developed innovative medicines are entering the reimbursement system at an accelerated pace; meanwhile, the commercial health insurance catalogue for innovative medicines provides an alternative reimbursement channel outside the national medical insurance scheme for high-cost cell and gene therapies. The announcement did not disclose the success rate of the negotiations or the average price reduction. Key points to watch: the reaction of the innovative drug sector on Monday, the pace at which hospitals across the country roll out these medicines, and the extent to which medicines on the commercial health insurance list will be made available in hospitals and pharmacies.

Source:National Healthcare Security Administration、Guangming Online (Xinhua News Agency)、The Paper

4. The Starship upper stage was caught by the launch tower for the first time; the Vulcan rocket, carrying 40 Amazon satellites, failed to launch

According to Space.com, the 15th test flight of SpaceX’s Starship took place at 17:47 on Friday, 13 November (Eastern Time) from Starport in Texas. The upper stage, Ship 42, entered orbit and deployed 26 Starlink V3 satellites. After orbiting the Earth for approximately 22.5 hours, it re-entered the atmosphere and was caught by the launch tower’s ‘Chopsticks’ robotic arm at approximately 16:20 on 14 November. This marked the first time a Starship upper stage had been recovered in this manner. Dan Yue of SpaceX described this as “the Holy Grail of spaceflight”. The first-stage booster, Booster 22, opted against recovery by the tower arm and landed in the Gulf of Mexico: the return ignition was terminated early due to a low-fuel warning, and after determining its position was incorrect, the booster opted for a sea landing; the cause is still under investigation.

A day later, ULA suffered a setback. According to Spaceflight Now, the Vulcan rocket lifted off from Cape Canaveral at 12:40 on Sunday, 15 November (Eastern Time), carrying 40 Amazon Leo internet satellites; however, an anomaly occurred approximately 10 minutes into the flight, and the satellites were not placed into orbit. This marks ULA’s first complete failure since its establishment in 2006, and was the fifth flight of the Vulcan rocket. Footage suggests that the solid rocket boosters functioned normally, whilst the first-stage burn time appeared to be slightly longer than expected; the Centaur upper stage exhibited an abnormal attitude during the initial phase of ignition. ULA stated that it would work with the customer to determine the cause. This launch was the first of 38 Vulcan launches purchased by Amazon; the LEO constellation requires over 3,300 satellites, and including this launch, only around 436 have been deployed so far, whilst Blue Origin’s New Glenn rocket has yet to resume flights following its explosion on the launch pad in May.

When these two developments are considered together, the contrast is striking: SpaceX is one step closer to achieving full reusability of Starship, and launch costs are expected to continue falling; meanwhile, Amazon’s Leo project, which relies on two major launch providers, has encountered temporary setbacks, and its network deployment may fall further behind Starlink. The Vulcan rocket may face a prolonged grounding, which will also affect the US Space Force’s national security launch missions. Key points to watch: the progress of ULA’s investigation and the timeline for resuming flights; whether Amazon will transfer more launches to SpaceX or Ariane 6; and the findings of the investigation into the Starship booster anomaly.

Source:Space.com、Spaceflight Now

5. Bitcoin fell to around US$63,000 at the weekend, its lowest level since August, whilst ETFs recorded net outflows for the seventh consecutive trading day

According to The Edge Malaysia, Bitcoin fell by 5.7 per cent during the US trading session on Saturday and by a further 1.7 per cent during the Asian trading session on Sunday, hitting a low of US$63,311—its lowest level since 17 August—representing a cumulative decline of approximately 25 per cent since 21 October; This year’s low was US$57,742 on 1 July. Ethereum fell to a low of US$1,731 on Sunday, its lowest level since 9 July. According to CoinGlass data, in the 24-hour period ending at 07:00 Singapore time on Sunday, cryptocurrency long positions were liquidated to the tune of approximately US$1.9 billion, of which US$684 million was in Bitcoin and US$466 million in Ethereum.

Funds continue to flow out of the market. According to CoinCentral, citing data from SoSoValue, US spot Bitcoin ETFs have recorded net outflows for seven consecutive trading days, totalling US$1.91 billion since 5 November. Outflows during the first nine trading days of November amounted to US$2.35 billion, marking the largest monthly outflow since June. Reasons cited in the report include rising expectations of interest rate hikes, AI-related risk aversion, the ongoing fallout from the $6 billion theft at Binance, and a chain reaction of margin calls triggered by the price falling below the 200-day moving average of approximately $73,000. GSR co-founder Rosenblum believes this is a technical correction. There have also been claims on social media that US investors sold Bitcoin ETFs to subscribe to Anthropic’s IPO, though this has not been confirmed.

Bitcoin was the only major risk asset to trade continuously over the weekend, and its decline can be seen as an early indicator of market sentiment: with the 10-year US Treasury yield above 5.1 per cent and a Fed rate rise in December already fully priced in, high-volatility assets are bearing the brunt of the impact. Last week, gold also fell below US$3,900 per ounce, indicating that this downturn is not merely a problem specific to the crypto market; a strengthening US dollar and rising real interest rates are simultaneously weighing on non-interest-bearing assets. Key points to watch going forward: whether the $60,000 level can be held, whether ETF fund flows will shift, and the impact on risk appetite of this week’s Nvidia earnings report and the Anthropic IPO.

Source:The Edge Malaysia、CoinCentral

Market Correlation and Today's Observation

When the markets open on Monday, investors will have to digest not only the weekend’s news but also a packed week ahead: On Monday, Japan’s preliminary third-quarter GDP figures and China’s October economic data are due; on Tuesday, Nvidia is set to report its earnings; on Wednesday, Anthropic’s pricing will be announced; on Wednesday and Thursday, the APEC meeting in Shenzhen and the trilateral summit will take place; and on Thursday, Anthropic is set to go public. According to a summary by InvestingLive, market expectations for China’s October data are for retail sales to rise by 0.8 per cent year-on-year (compared with 1.1 per cent in September), industrial output to grow by 5.3 per cent (compared with 5.5 per cent in September), and a 7.0 per cent year-on-year decline in fixed-asset investment for January–October (compared with a 7.2 per cent decline for January–September).

Uncertainty in the AI sector has deepened further. Rumours of Jensen Huang’s return may cause short-term, sentiment-driven volatility in Nvidia’s share price, but given the board’s cautious stance and the low probability of such a move, the direction of the stock will ultimately be determined by the data centre revenue and gross margin guidance in the earnings report. The decline in Bitcoin indicates that risk appetite for highly volatile assets is already very weak; should NVIDIA’s earnings report fall short of expectations, the pressure could spill over to other AI stocks and Anthropic’s valuation. On the domestic front, the inclusion of innovative drugs in the National Medical Insurance Reimbursement Catalogue is positive for the sector; however, following Friday’s sharp fall in the A-share market, investor attention is focused more on credit data and October’s economic figures. Furthermore, the People’s Bank of China has raised the foreign exchange reserve requirement ratio by 2 percentage points to 6 per cent, effective from 15 November, with the aim of slowing the appreciation of the renminbi. On the geopolitical front, according to the Anadolu Agency, the Iranian Revolutionary Guard reported over the weekend that two oil tankers had struck mines and caught fire south of the Strait of Hormuz. Such reports, alongside developments from the trilateral meeting in Shenzhen, are likely to influence oil prices on Monday.

Checklist:

  • Whether China’s October retail sales, industrial output and fixed-asset investment will exceed expectations, and the impact of Japan’s third-quarter GDP on expectations for a Bank of Japan interest rate rise in December
  • NVIDIA’s 17 November earnings report: Will revenue exceed the US$108 billion guidance? Fourth-quarter gross margin guidance, and the board’s response to rumours of Jensen Huang’s return
  • Will the trilateral meeting in Shenzhen on 19 November take place as scheduled, and will there be a joint statement on arms control or the Iran issue following the meeting?
  • The innovative pharmaceuticals sector’s reaction to the updated National Medical Insurance Reimbursement Catalogue
  • Progress on ULA’s investigation, the duration of the Vulcan rocket’s grounding, and adjustments to Amazon’s LEO launch plans
  • Can Bitcoin hold the $60,000 mark, and will outflows from spot ETFs continue?

Cover image:jay huang / Unsplash

  • Title: Daily Briefing | 16 November 2026: The Kremlin announces that the leaders of China, the US and Russia will meet in Shenzhen on 19 November; the FT reports that Jensen Huang is considering a return to Nvidia; 107 new medicines added to the 2026 National Reimbursement Drug List; Starship successfully catches upper stage with tower arm for the first time; first launch of the Vulcan rocket fails; Bitcoin falls to a three-month low
  • Author: AdenXie
  • Created at: 2026-11-16 09:00:00
  • Link: https://blog.adenxie.com.cn/2026/11/16/2026-11-16-daily-brief/
  • License: Unless otherwise noted, original text and images by AdenXie: CC BY-NC-SA 4.0; original code: GPL-3.0. Third-party material retains its original rights and licenses. Scope & exceptions.
Comments